The split-up of Galapagos is only the latest shake-up in the company in recent years. Other major events have included the ...

Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Belgian biotech Galapagos (NASDAQ:GLPG) announced a major restructuring drive on Wednesday, with plans to amend its 10-year collaboration with Gilead (NASDAQ:GILD) as part of its intention to ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines ...

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

As part of the restructuring, Galapagos and Gilead agreed to amend a major licensing and development deal they struck in 2019. Gilead will own about 25% of each of the two companies going forward ...